Key result
Primary site surgery significantly improved overall survival in patients with metastatic adrenocortical carcinoma compared to no surgery (HR 0.413; 95% CI 0.299-0.571; P<0.01).
Why the study?
Does primary site surgery improve survival in patients with metastatic adrenocortical carcinoma?
Population
290 metastatic adrenocortical carcinoma patients from the SEER database
Comparison
Primary site surgery vs No primary site surgery
Design
Cohort
Follow-up
median survival time 7 months
Authors
Loading...
Hypothesis-generating for primary site surgery in metastatic adrenocortical carcinoma; prospective randomized trials needed before clinical adoption.
Cohort (n=290)
Yes
Does primary site surgery improve survival in patients with metastatic adrenocortical carcinoma?
Hazard Ratio: 0.413 (95% CI 0.299–0.571)
p-value: p=<0.01
Primary site surgery in metastatic adrenocortical carcinoma is associated with significantly improved overall and cancer-specific survival.
Wang et al. (2017) conducted a cohort in Metastatic adrenocortical carcinoma (ACC) (n=290). Primary site surgery vs. No primary site surgery was evaluated on Overall survival (HR 0.413, 95% CI 0.299-0.571, p=<0.01). Primary site surgery significantly improved overall survival in patients with metastatic adrenocortical carcinoma compared to no surgery (HR 0.413; 95% CI 0.299-0.571; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: